Cidara Therapeutics (CDTX) Competitors $51.36 -0.14 (-0.26%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. PTCT, RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, SRRK, and VKTXShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), Scholar Rock (SRRK), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Its Competitors PTC Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx SpringWorks Therapeutics Avidity Biosciences ACADIA Pharmaceuticals Scholar Rock Viking Therapeutics Cidara Therapeutics (NASDAQ:CDTX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Does the media favor CDTX or PTCT? In the previous week, PTC Therapeutics had 2 more articles in the media than Cidara Therapeutics. MarketBeat recorded 8 mentions for PTC Therapeutics and 6 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 1.09 beat PTC Therapeutics' score of 0.94 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CDTX or PTCT more profitable? PTC Therapeutics has a net margin of 33.56% compared to Cidara Therapeutics' net margin of 0.00%. Cidara Therapeutics' return on equity of -73.04% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -73.04% -54.28% PTC Therapeutics 33.56%-78.56%32.11% Which has more volatility and risk, CDTX or PTCT? Cidara Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CDTX or PTCT? 35.8% of Cidara Therapeutics shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, CDTX or PTCT? Cidara Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$302K3,429.55-$169.83M-$29.47-1.74PTC Therapeutics$1.77B2.15-$363.30M$6.517.39 Do analysts rate CDTX or PTCT? Cidara Therapeutics presently has a consensus target price of $57.29, suggesting a potential upside of 11.53%. PTC Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 35.04%. Given PTC Therapeutics' higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11PTC Therapeutics 1 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.67 SummaryCidara Therapeutics and PTC Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-1.7420.3528.6119.64Price / Sales3,429.55304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book3.447.718.185.63Net Income-$169.83M-$55.11M$3.23B$257.73M7 Day Performance0.79%0.68%-0.25%0.07%1 Month Performance129.21%8.22%5.40%8.32%1 Year Performance296.95%-2.64%26.35%13.78% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.175 of 5 stars$51.37-0.3%$57.29+11.5%+311.9%$1.04B$302K-1.7490PTCTPTC Therapeutics4.4116 of 5 stars$47.98-2.2%$65.00+35.5%+44.1%$3.89B$806.78M7.371,410Analyst RevisionRAREUltragenyx Pharmaceutical4.3635 of 5 stars$39.61-0.8%$87.00+119.6%-38.8%$3.77B$560.23M-6.741,294Trending NewsAnalyst ForecastAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.73B$134.35M0.00600News CoverageMRUSMerus1.9315 of 5 stars$52.58-2.3%$84.64+61.0%-5.4%$3.73B$36.13M-12.8937News CoverageACLXArcellx2.4936 of 5 stars$65.55-2.4%$111.23+69.7%+7.6%$3.70B$107.94M0.0080News CoveragePositive NewsSWTXSpringWorks Therapeutics1.596 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsRNAAvidity Biosciences2.3275 of 5 stars$28.80-1.3%$65.59+127.7%-30.5%$3.52B$10.90M-9.60190Gap UpACADACADIA Pharmaceuticals4.0953 of 5 stars$20.88-0.3%$27.88+33.5%+22.1%$3.51B$957.80M15.24510Analyst RevisionSRRKScholar Rock3.0472 of 5 stars$35.48-1.4%$42.67+20.3%+320.8%$3.42B$33.19M-14.02140VKTXViking Therapeutics4.6165 of 5 stars$27.51-2.4%$87.15+216.8%-48.3%$3.17BN/A-23.9220Positive NewsUpcoming EarningsGap Up Related Companies and Tools Related Companies PTC Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Ascentage Pharma Group International Competitors Merus Competitors Arcellx Competitors SpringWorks Therapeutics Competitors Avidity Biosciences Competitors ACADIA Pharmaceuticals Competitors Scholar Rock Competitors Viking Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
